title: Telithromycin and the FDA: implications for the future.
authors.forename: David M
authors.initials: DM
authors.lastname: Shlaes
authors.forename: Robert C
authors.initials: RC
authors.lastname: Moellering
mesh_terms: D016907:Adverse Drug Reaction Reporting Systems / Q000706:statistics & numerical data; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D029481:Bronchitis, Chronic / Q000188:drug therapy*; D056486:Chemical and Drug Induced Liver Injury; D017277:Drug Approval; D006801:Humans; D048628:Ketolides / Q000009:adverse effects* / Q000627:therapeutic use; D018570:Risk Assessment; D012852:Sinusitis / Q000188:drug therapy* / Q000382:microbiology; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000900:Anti-Bacterial Agents; D048628:Ketolides; C106791:telithromycin